Common Causes

Thrombotic purpura is not a single disease; it results from a variety of triggers that disrupt the delicate balance of clot formation and dissolution. The most common causes include:

• Acquired Autoimmune TTP – antibodies that inhibit the enzyme ADAMTS13, which normally cleaves von Willebrand factor (VWF) multimers.
• Hereditary (Congenital) TTP – inherited deficiency of ADAMTS13.
• Atypical Hemolytic‑Uremic Syndrome (aHUS) – uncontrolled activation of the complement pathway.
• Shiga‑toxin–producing Bacterial Infection – most often E. coli O157:H7, leading to classic HUS.
• Drug‑Induced Thrombotic Microangiopathy – e.g., quinine, cyclosporine, tacrolimus, gemcitabine, bevacizumab.
• Pregnancy‑related TTP – can occur during the third trimester or postpartum.
• Malignancy‑associated Thrombotic Microangiopathy – especially with metastatic gastric, breast, or lung cancer.
• Systemic Lupus Erythematosus (SLE) and other autoimmune diseases – immune complexes may trigger endothelial injury.
• Severe Hypertension – malignant hypertension can cause endothelial damage and microthrombi.
• Genetic complement‑regulator mutations – rare mutations in genes such as CFH, CFI, or MCP that predispose to aHUS.

These triggers share a final common pathway: endothelial injury → platelet aggregation → formation of microvascular thrombi → consumption of platelets and red cell fragmentation.

Associated Symptoms

Thrombotic purpura usually presents with a constellation of systemic signs that reflect multi‑organ involvement. The classic “pentad” of TTP (present in only ~40% of cases) includes:

• Sudden appearance of purpuric or petechial skin lesions, often on the legs and buttocks.
• Fever (low‑grade to high‑grade).
• Neurologic changes – confusion, headaches, seizures, or focal deficits.
• Renal dysfunction – hematuria, proteinuria, or rising creatinine.
• Microangiopathic hemolytic anemia (MAHA) – fatigue, pallor, dark urine.

Other frequently reported symptoms are:

• Swollen or painful joints (arthralgia) due to microthrombi in synovial vessels.
• Abdominal pain or nausea, sometimes mimicking pancreatitis.
• Bleeding from gums, nose, or gastrointestinal tract because of thrombocytopenia.
• Shortness of breath or chest pain if cardiac microvasculature is affected.

When to See a Doctor

Because thrombotic purpura can progress rapidly to organ failure, early evaluation is critical. Seek medical care promptly if you notice:

• Sudden, unexplained purpuric spots that do not blanch when pressed.
• Bruising or bleeding that occurs without injury.
• New‑onset confusion, slurred speech, severe headache, or seizures.
• Dark (tea‑colored) urine or a marked decrease in urine output.
• Fever >38 °C (100.4 °F) accompanied by the above skin changes.
• Rapidly worsening fatigue, shortness of breath, or chest discomfort.

If any of these symptoms develop after taking a medication known to cause thrombotic microangiopathy (e.g., quinine, chemotherapy agents), discontinue the drug only under medical supervision and contact your provider immediately.

Diagnosis

Diagnosing thrombotic purpura requires a combination of clinical suspicion, laboratory testing, and occasionally imaging. The typical work‑up includes:

1. Complete Blood Count (CBC) – Expect low platelets (<150 × 10⁹/L) and anemia with a left‑shifted smear.
2. Peripheral Blood Smear – Presence of schistocytes (fragmented red cells) is a hallmark of microangiopathic hemolysis.
3. Lactate Dehydrogenase (LDH) – Elevated due to red‑cell destruction.
4. Haptoglobin – Usually low or undetectable because it binds free hemoglobin.
5. Serum Creatinine & BUN – Assess renal involvement.
6. Coagulation Profile – PT/INR and aPTT are typically normal, helping differentiate from disseminated intravascular coagulation (DIC).
7. ADAMTS13 Activity Test – Severe deficiency (<10% activity) strongly suggests autoimmune TTP. Results may take several days, so treatment often starts before the result returns.
8. Complement Levels (C3, C4) and Genetic Testing – Helpful for aHUS.
9. Urinalysis – Hematuria, proteinuria, or red‑cell casts indicate renal microvascular injury.
10. Imaging (if neurologic symptoms occur) – MRI or CT to exclude stroke or hemorrhage.

Because delayed treatment increases mortality (up to 90% without therapy), clinicians frequently start empiric plasma exchange (PEX) when TTP is suspected, even before definitive test results.

Treatment Options

Management combines rapid removal of circulating autoantibodies, suppression of the immune response, and supportive care. The approach differs slightly between TTP and aHUS.

Acute Medical Therapy

• Therapeutic Plasma Exchange (TPE) – First‑line for TTP; removes anti‑ADAMTS13 antibodies and replaces functional ADAMTS13. Typical schedule: daily exchanges of 1–1.5 × plasma volume until platelet count >150 × 10⁹/L for two consecutive days.
• Corticosteroids – High‑dose methylprednisolone (1 mg/kg) or prednisone (1 mg/kg) to dampen the autoimmune response.
• Rituximab – Anti‑CD20 monoclonal antibody; increasingly used early to shorten TPE duration and prevent relapses.
• Caplacizumab – Nanobody that blocks VWF‑platelet interaction; approved for acquired TTP and shown to reduce time to platelet normalization.
• Eculizumab or Ravulizumab – Terminal complement inhibitors; first‑line for aHUS and increasingly used in complement‑mediated TTP.
• Immunosuppressants (e.g., cyclophosphamide, mycophenolate) – Considered for refractory disease.

Supportive Care

• Transfusion of red blood cells for symptomatic anemia (avoid platelet transfusion unless life‑threatening bleeding).
• Avoid nephrotoxic drugs; adjust doses for renal impairment.
• Maintain adequate blood pressure; treat malignant hypertension promptly.
• Monitor electrolytes, especially potassium and calcium, during TPE.
• Prophylactic anticoagulation is generally not indicated because of the bleeding risk, but low‑dose aspirin may be used after platelet recovery under specialist guidance.

Home & Long‑Term Management

• Follow‑up ADAMTS13 activity testing every 3–6 months for acquired TTP.
• Vaccinations (e.g., meningococcal vaccine) before initiating complement inhibitors like eculizumab.
• Education on early signs of relapse – recurrent purpura, bruising, fatigue.
• Pregnancy counseling for women with prior TTP; close obstetric‑hematology collaboration is essential.

Prevention Tips

Because many triggers are unavoidable (genetic mutations, infections), prevention focuses on reducing modifiable risk factors and early recognition:

• Medication Awareness – Discuss with your provider before starting drugs known to cause thrombotic microangiopathy (e.g., quinine, certain chemotherapy agents).
• Infection Control – Proper food handling to avoid E. coli O157:H7; treat gastrointestinal infections promptly.
• Blood Pressure Management – Keep hypertension well‑controlled; use home BP monitors.
• Vaccination – Stay up‑to‑date on meningococcal, pneumococcal, and influenza vaccines, especially if you receive complement inhibitors.
• Regular Check‑ups – For individuals with known ADAMTS13 deficiency or complement mutations, routine labs can catch early drops in platelets.
• Lifestyle Choices – Avoid smoking, excessive alcohol, and illicit drugs that may worsen endothelial health.

Emergency Warning Signs

References

1. Mayo Clinic. “Thrombotic thrombocytopenic purpura (TTP).” Updated 2023. https://www.mayoclinic.org
2. Cleveland Clinic. “Thrombotic Thrombocytopenic Purpura (TTP).” 2022. https://my.clevelandclinic.org
3. Joly BS, et al. “Management of acquired thrombotic thrombocytopenic purpura.” Blood. 2022;140(19):2058‑2070.
4. George JN, Nester CM. “Syndromes of thrombotic microangiopathy.” New England Journal of Medicine. 2022;386: 1915‑1926.
5. National Institutes of Health. “Atypical Hemolytic Uremic Syndrome (aHUS).” 2023. https://www.nhlbi.nih.gov
6. World Health Organization. “Guidelines for the management of hemolytic‑uremic syndrome.” 2021.